The request and info follows:
“Prostate cancer is the most common form of cancer, excluding skin cancers, in American men. Men who are older, are of African-American descent, and those with a family history of the disease are at a greater risk for developing prostate cancer. In fact, as men mature, the likelihood of developing the disease increases exponentially. More than 65 percent of disease occurrence is in men older than age 65.
Researchers currently are conducting a study to compare the effectiveness of two procedures in treating low-risk, localized prostate cancer. One of the procedures being tested is cryotherapy (freeze therapy), a commonly used minimally invasive treatment for localized prostate cancer that already is approved for treatment by the U.S. Food and Drug Administration (FDA). In the study, cryotherapy will be compared with an investigational procedure called high-intensity focused ultrasound (HIFU). This procedure is not approved by the FDA. This comparison will help researchers understand if HIFU is as safe and effective as cryotherapy.
Both of the procedures being studied are less invasive than other options. In the last several years, minimally invasive treatment options, of which cryotherapy is one, have been examined closer to determine what benefits they may offer over other standard therapies. The goal of minimally invasive options is to reduce the impact of the treatment on the patient, resulting in quicker recovery and fewer side effects, while maintaining the effectiveness of standard treatments. “
If you are interested in learning more about the study and prescreen, call toll-free at 1-888-707-3737 or visit www.PCaResearch.com.